MX2020013181A - Metodo para administrar una cantidad terapeuticamente efectiva de 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-th iazolidin-2,4-diona. - Google Patents

Metodo para administrar una cantidad terapeuticamente efectiva de 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-th iazolidin-2,4-diona.

Info

Publication number
MX2020013181A
MX2020013181A MX2020013181A MX2020013181A MX2020013181A MX 2020013181 A MX2020013181 A MX 2020013181A MX 2020013181 A MX2020013181 A MX 2020013181A MX 2020013181 A MX2020013181 A MX 2020013181A MX 2020013181 A MX2020013181 A MX 2020013181A
Authority
MX
Mexico
Prior art keywords
administering
compound
patient
thiazolidine
dione
Prior art date
Application number
MX2020013181A
Other languages
English (en)
Inventor
Lalanza Maria Pilar Pizcueta
Pedemonte Marc Martinell
Laguna Guillem Pina
Uwe Meya
Alan Bye
Original Assignee
Minoryx Therapeutics S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minoryx Therapeutics S L filed Critical Minoryx Therapeutics S L
Publication of MX2020013181A publication Critical patent/MX2020013181A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente descripción proporciona métodos para tratar una enfermedad o trastorno en un paciente que comprende administrar 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-ti azolidin-2,4-diona ("Compuesto (1)"), o una sal farmacéuticamente aceptable de la misma, al paciente, en donde el paciente logra una concentración plasmática umbral de estado estacionario del Compuesto (1). La presente descripción también proporciona métodos para administrar una cantidad terapéuticamente efectiva del compuesto (1), o una sal farmacéuticamente aceptable del mismo, a un paciente. El compuesto (1) es un agonista de PPAR-? que se usa para tratar una variedad de enfermedades y trastornos que incluyen, pero no se limitan a, esteatohepatitis no alcohólica y enfermedades de sistema nervioso central, por ejemplo, adrenoleucodistrofia enlazada a X, ataxia de Friedreich.
MX2020013181A 2018-06-06 2019-06-06 Metodo para administrar una cantidad terapeuticamente efectiva de 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-th iazolidin-2,4-diona. MX2020013181A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18382398 2018-06-06
PCT/IB2019/054743 WO2019234689A1 (en) 2018-06-06 2019-06-06 Method of administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione

Publications (1)

Publication Number Publication Date
MX2020013181A true MX2020013181A (es) 2021-02-26

Family

ID=62716009

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020013181A MX2020013181A (es) 2018-06-06 2019-06-06 Metodo para administrar una cantidad terapeuticamente efectiva de 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-th iazolidin-2,4-diona.

Country Status (14)

Country Link
US (1) US20210308113A1 (es)
EP (1) EP3801516A1 (es)
JP (1) JP7549344B2 (es)
KR (1) KR20210031435A (es)
CN (1) CN112512524A (es)
AU (1) AU2019283649A1 (es)
BR (1) BR112020024917A2 (es)
CA (1) CA3102407A1 (es)
CL (1) CL2020003162A1 (es)
EA (1) EA202092953A1 (es)
IL (1) IL279183A (es)
MX (1) MX2020013181A (es)
SG (1) SG11202012045UA (es)
WO (1) WO2019234689A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
EP3801515A1 (en) 2018-06-06 2021-04-14 Minoryx Therapeutics S.L. 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases
WO2024141951A1 (en) 2022-12-28 2024-07-04 Minoryx Therapeutics S.L. Optimized dosing of leriglitazone

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2529211T3 (es) * 2005-11-29 2015-02-18 Children's Hospital Medical Center Optimización e individualización de la selección y dosificación de medicamentos
US20140114676A1 (en) * 2012-10-23 2014-04-24 Theranos, Inc. Drug Monitoring and Regulation Systems and Methods
MX2016012687A (es) 2014-04-02 2017-04-27 Minoryx Therapeutics S L Derivados de 2,4-tiazolidindiona en el tratamiento de trastornos del sistema nervioso central.
DK3559010T3 (da) 2016-12-23 2022-08-15 Minoryx Therapeutics S L Fremgangsmåde til fremstilling af 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedion og salte deraf

Also Published As

Publication number Publication date
IL279183A (en) 2021-01-31
CL2020003162A1 (es) 2021-07-02
JP2021527045A (ja) 2021-10-11
KR20210031435A (ko) 2021-03-19
BR112020024917A2 (pt) 2021-03-09
EA202092953A1 (ru) 2021-04-12
SG11202012045UA (en) 2021-01-28
EP3801516A1 (en) 2021-04-14
AU2019283649A1 (en) 2021-01-07
CA3102407A1 (en) 2019-12-12
JP7549344B2 (ja) 2024-09-11
US20210308113A1 (en) 2021-10-07
WO2019234689A1 (en) 2019-12-12
CN112512524A (zh) 2021-03-16

Similar Documents

Publication Publication Date Title
MX2020013181A (es) Metodo para administrar una cantidad terapeuticamente efectiva de 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-th iazolidin-2,4-diona.
CL2021000491A1 (es) Combinaciones para tratamiento de ehna/ehgna y enfermedades relacionadas
JP2005536475A5 (es)
BRPI0108977B8 (pt) compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo
NZ604004A (en) Pyridone and aza-pyridone compounds and methods of use
JP2014528486A5 (es)
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
EA200601799A1 (ru) Гидразидсодержащие соединения - ингибиторы cftr и их применение
JP2010525056A5 (es)
EA201991078A1 (ru) Креноланиб для лечения пролиферативных расстройств, связанных с мутацией flt3
US20190216804A1 (en) Methods and pharmaceutical compositions for the treatment of fibrosis
HUP0300479A2 (hu) PPAR-gamma agonisták alkalmazása neutrofil okozta betegségek kezelésére
NZ578928A (en) Methods to increase mobility of hematopoietic stem cells by use of a lipopeptide compound and treatment of associated diseases
EP1758998A4 (en) OLIGORIBONUCLEOTIDES AND METHODS OF USE THEREOF IN THE TREATMENT OF FIBROUS CONDITIONS AND OTHER DISEASES
JP2007538064A (ja) 化学または生物兵器に曝露された患者を処置するための肥満細胞阻害剤の使用法
EA200701680A1 (ru) Лекарственная форма для перорального введения, содержащая розиглитазон
CO5261586A1 (es) Uso de pramipexol en el tratamiento de transtornos de adiccion
EA025948B1 (ru) КОМБИНАЦИЯ ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТ-3-КИНАЗЫ (PI3K) И ИНГИБИТОРА mTOR
MXPA04000839A (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas.
CA2907049A1 (en) Use of ep4 receptor antagonists in the treatment of cartilage disease
MX2013008715A (es) Uso de (s) -esmolol para controlar la irritacion venosa asociada con el tratamiento de un padecimiento cardiaco.
CY1124116T1 (el) 5-[[4-[2-[5-(1-υδροξυαιθυλ)πυριδιν-2-υλ]αιθοξυ]φαινυλ]μεθυλ]-1,3-θειαζολιδινο-2,4-διονη για την θεραπεια της μη αλκοολικης λιπωδους νοσου του ηπατος
EA202190544A1 (ru) Применение распадающихся в полости рта таблеток рилузола для лечения заболеваний
RU2015126293A (ru) Производные тиазола в качестве ингибиторов тирозинкиназы брутона
Sharif Novel potential treatment modalities for ocular hypertension: focus on angiotensin and bradykinin system axes